[{"data":1,"prerenderedAt":207},["ShallowReactive",2],{"/whitepapers/eu-ctr":3},{"id":4,"title":5,"body":6,"category":196,"description":197,"extension":198,"meta":199,"navigation":200,"path":201,"pdf":202,"preview":203,"seo":204,"stem":205,"__hash__":206},"whitepapers/whitepapers/eu-ctr.md","EU Clinical Trials Regulation and Data Sovereignty: What eClinical SaaS Companies Need to Build Now",{"type":7,"value":8,"toc":184},"minimark",[9,14,18,21,24,28,31,34,37,40,43,46,49,53,56,59,62,65,68,72,75,78,81,84,87,90,93,97,100,103,106,109,112,115,119,122,125,128,131,134,137,140,144,147,150,153,156,159,162,166,169,172,175],[10,11,13],"h2",{"id":12},"executive-summary","Executive Summary",[15,16,17],"p",{},"The EU Clinical Trials Regulation (CTR, Regulation 536/2014) is now fully operational. Since January 2025, all clinical trials in the European Union must be submitted and managed through the Clinical Trials Information System (CTIS), the centralized EMA portal that replaced 27 separate national procedures. For eClinical SaaS vendors (EDC systems, electronic Trial Master File (eTMF) platforms, CTMS, IRT/RTSM solutions) CTR compliance is not optional, and it has a data architecture dimension that many vendors have underestimated.",[15,19,20],{},"The CTR does not specify encryption standards. But it operates within a GDPR framework that requires technical measures appropriate to the risk, and the data sovereignty expectations embedded in the regulation, including the requirement that competent national authorities can access trial data on demand, have direct implications for how patient data is stored, encrypted, and controlled. Combine this with the unresolved tension between GDPR transfer requirements and the US CLOUD Act, and eClinical SaaS companies running on US hyperscalers face a structural problem: their architecture may be legally incompatible with the data access obligations the CTR creates.",[15,22,23],{},"Customer-controlled encryption, specifically BYOK with HSM-backed, jurisdictionally isolated key management is the architectural response that resolves this tension. This whitepaper explains why, and what it means for your platform.",[10,25,27],{"id":26},"_1-the-ctr-in-force-what-changed-in-2025","1. The CTR in Force: What Changed in 2025",[15,29,30],{},"Regulation (EU) No 536/2014 replaced Directive 2001/20/EC, the prior framework that required sponsors to navigate separate competent authority and ethics committee approvals in each EU member state where a trial was to be conducted. The CTR created a single application process through CTIS, with coordinated assessment across member states and a defined authorization timeline.",[15,32,33],{},"The regulation entered into force in January 2022, with a three-year transition period. Since January 2025, all new trials must use the CTIS pathway, and previously approved trials under the old directive have been migrated or closed out.",[15,35,36],{},"For eClinical SaaS companies, the practical implications of full CTR applicability include:",[15,38,39],{},"Data submitted through CTIS is accessible to all relevant national competent authorities (NCAs) and the EMA. This creates a federated data access model that is fundamentally different from the bilateral sponsor-authority relationships that existed under the directive.",[15,41,42],{},"Trial data must be archived for a minimum of 25 years after trial conclusion (Article 58). This retention requirement applies to the complete investigational medicinal product dossier, not just published results. eClinical platforms that are the systems of record for trial data carry this archiving obligation downstream.",[15,44,45],{},"Transparency and publication requirements under CTR Article 37 and 38 mean that trial results, including patient-level summary data, must be submitted to CTIS within defined timeframes. The data must be in formats that are accessible and machine-readable.",[15,47,48],{},"None of these requirements are purely technical. But each has a data architecture implication: who can access what data, under what conditions, and with what audit trail.",[10,50,52],{"id":51},"_2-the-data-sovereignty-problem-for-us-based-cloud-platforms","2. The Data Sovereignty Problem for US-Based CLOUD Platforms",[15,54,55],{},"Most eClinical SaaS companies including many founded in Europe run their infrastructure on AWS, Azure, or Google Cloud, often in regions outside the EU. This is not inherently problematic from a GDPR standpoint, provided appropriate transfer mechanisms (SCCs, TIA) are in place. But the CTR and GDPR intersection creates a specific sovereignty tension that cloud-region selection alone does not resolve.",[15,57,58],{},"The US CLOUD Act (Clarifying Lawful Overseas Use of Data Act, 2018) allows US law enforcement to compel US-headquartered cloud providers to produce data stored anywhere in the world, including in EU regions. This means that EU-region-hosted clinical trial data on AWS, Azure, or Google Cloud is potentially accessible to US authorities under US law, regardless of GDPR protections.",[15,60,61],{},"The European Data Protection Board has been explicit that this tension is not resolved by storing data in EU regions if the cloud provider is subject to US law. The Schrems II ruling confirmed that the legal framework of the data importer, not just the physical location of the data, is what matters for transfer risk assessment.",[15,63,64],{},"For eClinical SaaS vendors, this creates a specific liability: sponsor customers, who are the data controllers under GDPR for patient data, are increasingly requiring contractual assurances that their data cannot be accessed by non-EU entities under non-EU law. If your platform cannot provide that assurance architecturally, you are losing enterprise EU pharma business to competitors who can.",[15,66,67],{},"The architectural solution is not to move off hyperscalers. That is operationally impractical and commercially uncompetitive. The solution is to remove the hyperscaler from the encryption key chain.",[10,69,71],{"id":70},"_3-encryption-key-control-as-a-sovereignty-mechanism","3. Encryption Key Control as a Sovereignty Mechanism",[15,73,74],{},"In a standard cloud KMS arrangement, the cloud provider manages encryption keys. Data at rest in S3, Azure Blob Storage, or Google Cloud Storage is encrypted, but the keys are held and managed by the cloud provider. A CLOUD Act request to the cloud provider yields plaintext data.",[15,76,77],{},"In a BYOK arrangement with externally managed keys, the cloud provider holds only ciphertext. Encryption keys are held in an HSM operated outside the cloud provider's infrastructure, by a legal entity not subject to US law. A CLOUD Act request to the cloud provider yields ciphertext that cannot be decrypted without the key, which the cloud provider does not have.",[15,79,80],{},"This architectural change has a legal effect: it removes the cloud provider from the data access chain. For GDPR purposes, it means that even if the cloud provider is compelled to produce data, the data produced is not personal data, it is unintelligible ciphertext. The practical data sovereignty guarantee is real rather than contractual.",[15,82,83],{},"For eClinical SaaS vendors, implementing BYOK with externally managed keys serves three constituencies simultaneously:",[15,85,86],{},"Sponsor customers (data controllers) get a demonstrable technical guarantee that their patient data cannot be accessed by the cloud provider or by US law enforcement acting on the cloud provider, satisfying their own DPA obligations to data subjects.",[15,88,89],{},"National competent authorities get an architecture that maintains EU-jurisdictional control over clinical trial data, aligned with the data sovereignty expectations embedded in the CTR.",[15,91,92],{},"The eClinical vendor gets a defensible answer to the \"where are my data and who can access them\" question that enterprise pharma procurement teams increasingly ask before signing.",[10,94,96],{"id":95},"_4-what-this-means-for-edc-etmf-ctms-and-irt-vendors","4. What This Means for EDC, eTMF, CTMS, and IRT Vendors",[15,98,99],{},"The CTR data sovereignty issue applies differently across the eClinical platform categories, based on the sensitivity and regulatory significance of the data each system holds.",[15,101,102],{},"Electronic Data Capture (EDC) systems hold primary clinical data, patient-level trial data that is special category data under GDPR Article 9. This is the highest-sensitivity tier. EDC vendors face the most acute data sovereignty obligation and the most regulatory scrutiny. BYOK is essentially mandatory for any EDC vendor targeting regulated EU markets.",[15,104,105],{},"Electronic Trial Master File (eTMF) systems hold the essential documents that form the regulatory record of the trial. Under CTR Article 58, this record must be archived for 25 years. The long retention horizon combined with the document-level regulatory significance makes eTMF data sovereignty architecturally important, particularly for the long-tail archiving obligation.",[15,107,108],{},"Clinical Trial Management Systems (CTMS) hold operational and site data that is less likely to contain patient-identifiable information but often holds commercially sensitive protocol and site information. Data sovereignty is a commercial as well as regulatory concern here.",[15,110,111],{},"IRT/RTSM (Interactive Response Technology / Randomization and Trial Supply Management) systems hold randomization codes and treatment assignments that are critical to trial integrity. Unauthorized access to unblinded randomization data can compromise the scientific validity of the trial. Key management for IRT systems has a scientific integrity dimension beyond pure data protection compliance.",[15,113,114],{},"In each case, the practical requirement is the same: the eClinical vendor needs to be able to tell a sponsor customer, truthfully, that the cloud provider cannot access the data in plaintext, and that the customer's own security team can control and if necessary revoke key access.",[10,116,118],{"id":117},"_5-implementing-byok-for-eclinical-platforms-architecture-considerations","5. Implementing BYOK for eClinical Platforms: Architecture Considerations",[15,120,121],{},"Implementing BYOK for an eClinical SaaS platform involves decisions at several layers of the stack.",[15,123,124],{},"Key scope. The first decision is what data is covered by customer-controlled keys. For EDC systems, the answer should be all patient data: at minimum, all data that qualifies as special category under GDPR Article 9. For eTMF and CTMS, the scope should be defined by sponsor contract requirements and the platform's own data classification policy.",[15,126,127],{},"Key tenancy model. Most eClinical platforms support multiple sponsor customers on shared infrastructure. The key management architecture should support per-sponsor key isolation, each sponsor's data encrypted under keys that only that sponsor's security team controls. This is a multi-tenancy requirement at the encryption layer, not just at the application layer.",[15,129,130],{},"Cloud KMS integration. Native BYOK integration with AWS KMS External Key Store (XKS), Azure Key Vault Managed HSM BYOK, and Google Cloud KMS External Key Manager allows the platform to use customer-controlled keys for all cloud-native encryption operations including storage, database encryption, and message queuing without application-layer changes. The cloud KMS handles encryption operations using the external key, which never leaves the external HSM.",[15,132,133],{},"Key governance and lifecycle. Customer-controlled keys need customer-accessible governance controls: key rotation, suspension, revocation. The external key management service must expose these controls in a way that the sponsor customer's security team can actually use: through an API, a management console, or a delegated managed service.",[15,135,136],{},"Audit logging. Every key access event must be logged with the identity of the requestor (the cloud service), the key used, the data asset accessed (if identifiable), and the timestamp. Logs must be exportable for regulatory inspection. Under CTR's audit trail requirements and GCP (ICH E6(R3)) data integrity standards, this logging is not optional.",[15,138,139],{},"Long-term key availability. CTR's 25-year archiving requirement creates a key management challenge that most BYOK implementations ignore: the keys used to encrypt archived data must remain available (or be securely re-encrypted with new keys) for the full 25-year retention period. Any BYOK architecture for eClinical platforms must address long-horizon key custody.",[10,141,143],{"id":142},"_6-how-alcazarix-supports-eclinical-data-sovereignty","6. How Alcazarix Supports eClinical Data Sovereignty",[15,145,146],{},"Alcazarix provides managed BYOK as a service with the architecture and jurisdictional characteristics required for eClinical CTR compliance.",[15,148,149],{},"Our key management infrastructure runs in two jurisdictionally isolated environments: Alcazarix Canada for North American deployments and Alcazarix Germany for EU deployments, operated by separate legal entities, Alcazarix, Inc. and Alcazarix Europe B.V. respectively. This means that EU clinical trial data encrypted under keys managed by Alcazarix Europe B.V. is subject exclusively to European law, with no US parent company able to be compelled under US surveillance or law enforcement statutes.",[15,151,152],{},"We support per-sponsor key isolation natively, allowing eClinical SaaS vendors to implement multi-tenant key management where each sponsor controls their own key namespace. This aligns with GCP expectations that sponsors maintain control over their trial data.",[15,154,155],{},"Our integrations with AWS KMS XKS, Azure Key Vault Managed HSM BYOK, and Google Cloud KMS EKM cover the cloud platforms where most eClinical SaaS is deployed, without requiring application-layer changes to the platform. Key operations are performed by Alcazarix infrastructure, keys never leave our HSMs in plaintext.",[15,157,158],{},"For the long-horizon archiving requirement, we provide key custody agreements that address the 25-year retention obligation, including documented processes for key re-encryption and long-term custody transfer.",[15,160,161],{},"Alcazarix is a purpose-built alternative to legacy HSM vendors. We do not require on-premises HSM hardware, FIPS certification overhead, or the appliance-count pricing models that make Thales and Utimaco cost-prohibitive for SaaS deployment models.",[10,163,165],{"id":164},"_7-conclusion","7. Conclusion",[15,167,168],{},"The EU CTR's full applicability in 2025 has moved data sovereignty from a future concern to a present obligation for eClinical SaaS vendors. The combination of GDPR's transfer requirements, the US CLOUD Act's reach into EU-region cloud storage, and the CTR's federated data access model creates a structural problem that cannot be resolved by contract alone. It requires an architectural response.",[15,170,171],{},"Customer-controlled encryption: BYOK with HSM-backed, jurisdictionally isolated external key management is that response. It removes the cloud provider from the data access chain, creates a demonstrable technical guarantee of EU jurisdictional control, and positions eClinical SaaS vendors to answer the data sovereignty questions that enterprise EU pharma customers are increasingly asking before signing.",[15,173,174],{},"The time to build this architecture is not when a sponsor customer asks for it in a procurement questionnaire. The time to build it is now, while CTR compliance programs are still being finalized and the architecture can be designed in rather than bolted on.",[15,176,177,178,183],{},"For more on how Alcazarix supports eClinical data sovereignty, contact us at ",[179,180,182],"a",{"href":181},"mailto:hello@alcazarix.com","hello@alcazarix.com"," or visit alcazarix.com.",{"title":185,"searchDepth":186,"depth":186,"links":187},"",2,[188,189,190,191,192,193,194,195],{"id":12,"depth":186,"text":13},{"id":26,"depth":186,"text":27},{"id":51,"depth":186,"text":52},{"id":70,"depth":186,"text":71},{"id":95,"depth":186,"text":96},{"id":117,"depth":186,"text":118},{"id":142,"depth":186,"text":143},{"id":164,"depth":186,"text":165},"EU Clinical Trials Regulation","How eClinical SaaS vendors can address the CLOUD Act and GDPR data sovereignty tension introduced by CTR with customer-controlled encryption key management.","md",{},true,"/whitepapers/eu-ctr","/whitepapers/Alcazarix_Whitepaper_EU_CTR_Data_Sovereignty_eClinical_SaaS.pdf","/whitepapers/preview_EU_CTR_Data_Sovereignty_eClinical_SaaS.png",{"title":5,"description":197},"whitepapers/eu-ctr","GUYsaRRUCD_c8E8SFU-MRE6PEZl3GttADyEH74DSQKU",1781816061892]